88.05 0.00 (0.00%)
After hours: 4:07PM EDT
|Bid||87.01 x 1100|
|Ask||90.82 x 1000|
|Day's Range||87.96 - 90.83|
|52 Week Range||75.81 - 106.74|
|Beta (3Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 23, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||119.87|
How Major Rare Disease Pharma Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 32.04% for BioMarin Pharmaceutical (BMRN) based on the stock’s
Even in development-averse Marin, new hotel proposals are being stuffed into the Bay Area pipeline in an effort to meet accelerating demand.
Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $2.02 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...
SAN RAFAEL, Calif. , March 6, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Cowen ...
A handful of Silicon Valley's largest technology companies, including Facebook and Broadcom, pay their median employee more than double the region's per capita income.
Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors
SAN RAFAEL, Calif., March 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion for the company's Marketing Authorization Application (MAA) for Palynziq® (pegvaliase) Injection to reduce blood phenylalanine (Phe) concentrations in patients with phenylketonuria (PKU) aged 16 and older, who have inadequate blood Phe control (blood Phe levels greater than 600 micromol/L) despite prior management with available treatment options. In addition, the CHMP noted that the data collected in the Phase 3 trial and extension study was suggestive of an improvement in inattention and mood symptoms.
Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.
SAN FRANCISCO, Feb. 26, 2019 /PRNewswire/ -- As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions, BioMarin Pharmaceutical Inc. (BMRN), Invitae Corporation (NVTA), Stoke Therapeutics and Xenon Pharmaceuticals (XENE) today announced the expansion of Behind the Seizure, an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy. Previously available to patients ages 2-4 years, the program will expand eligibility to make no-cost genetic testing available for healthcare providers to order for children who have had an unprovoked seizure from birth up to age five (0 to 60 months).
Roche Holdings AG Basel ADR (OTC: RHHBY )'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE ) has sparked a rally in the latter's shares. The Analysts ...
Investing.com – Swiss-based Roche Holding's bumper offer to acquire Spark Therapeutics on Monday propped up the healthcare sector and fueled speculation on Wall Street that more merger activity is in the pipeline for gene therapy stocks.
Merck (MRK) shares have been on a roll the past year, up nearly 50% to more than $80 in the past year. In a recent article in FiercePharma, Morningstar analysts said that U.S.-based companies may have to go the acquisition route to increase their high-value pipelines. Warning! GuruFocus has detected 6 Warning Signs with MRK.
BioMarin Pharmaceutical stock slipped Friday after the biotech late Thursday reported lagging fourth-quarter revenue. The company said its newest drug cannibalized sales of another.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 21.) Eli Lilly And Co (NYSE: LLY ) Gossamer ...
The San Rafael, California-based company said it had a loss of 3 cents per share. Losses, adjusted for one-time gains and costs, were 6 cents per share. The results missed Wall Street expectations. The ...
- Total Revenues for 2018 Grow 14% Year-over-Year to $1.5 Billion - As of February 15, 2019, 335 U.S. Commercial Patients Receiving Treatment with Palynziq® - In Europe, CHMP Opinion for Palynziq Anticipated ...